| Term | Count | % | | OCULAR HYPERAEMIA | 458 | 9.50% |
| EYE IRRITATION | 411 | 8.53% |
| EYE PAIN | 287 | 5.95% |
| EYE PRURITUS | 226 | 4.69% |
| DRUG INEFFECTIVE | 205 | 4.25% |
| DEATH | 196 | 4.07% |
| VISION BLURRED | 166 | 3.44% |
| HEADACHE | 158 | 3.28% |
| EYE SWELLING | 122 | 2.53% |
| DRY EYE | 107 | 2.22% |
| INTRAOCULAR PRESSURE INCREASED | 94 | 1.95% |
| PHOTOPHOBIA | 85 | 1.76% |
| LACRIMATION INCREASED | 74 | 1.54% |
| DIZZINESS | 69 | 1.43% |
| DYSPNOEA | 69 | 1.43% |
| HYPERSENSITIVITY | 64 | 1.33% |
| OFF LABEL USE | 63 | 1.31% |
| FATIGUE | 56 | 1.16% |
| PRURITUS | 54 | 1.12% |
| COUGH | 51 | 1.06% |
| VISUAL IMPAIRMENT | 50 | 1.04% |
| PAIN | 44 | 0.91% |
| NAUSEA | 43 | 0.89% |
| EYE DISCHARGE | 42 | 0.87% |
| RASH | 41 | 0.85% |
| URINARY TRACT INFECTION | 40 | 0.83% |
| PRODUCT DOSE OMISSION ISSUE | 39 | 0.81% |
| ERYTHEMA | 37 | 0.77% |
| FOREIGN BODY SENSATION IN EYES | 37 | 0.77% |
| OCULAR DISCOMFORT | 37 | 0.77% |
| GLAUCOMA | 36 | 0.75% |
| PRODUCT QUALITY ISSUE | 35 | 0.73% |
| DIARRHOEA | 34 | 0.71% |
| NO ADVERSE EVENT | 32 | 0.66% |
| FALL | 31 | 0.64% |
| ARTHRALGIA | 30 | 0.62% |
| DRUG HYPERSENSITIVITY | 28 | 0.58% |
| NASOPHARYNGITIS | 28 | 0.58% |
| ERYTHEMA OF EYELID | 27 | 0.56% |
| ALOPECIA | 26 | 0.54% |
| BLOOD PRESSURE INCREASED | 26 | 0.54% |
| CEREBROVASCULAR ACCIDENT | 26 | 0.54% |
| VISUAL ACUITY REDUCED | 26 | 0.54% |
| DRUG DOSE OMISSION | 25 | 0.52% |
| CATARACT | 24 | 0.50% |
| EYE INFLAMMATION | 24 | 0.50% |
| MALAISE | 24 | 0.50% |
| WRONG TECHNIQUE IN PRODUCT USAGE PROCESS | 24 | 0.50% |
| DYSPHONIA | 23 | 0.48% |
| INSOMNIA | 23 | 0.48% |
| RHINORRHOEA | 23 | 0.48% |
| SYNCOPE | 23 | 0.48% |
| BLEPHARITIS | 22 | 0.46% |
| EYELID IRRITATION | 22 | 0.46% |
| OROPHARYNGEAL PAIN | 22 | 0.46% |
| HYPERTENSION | 21 | 0.44% |
| ABNORMAL SENSATION IN EYE | 20 | 0.41% |
| ASTHENIA | 20 | 0.41% |
| CONSTIPATION | 20 | 0.41% |
| COVID-19 | 20 | 0.41% |
| MUSCULAR WEAKNESS | 20 | 0.41% |
| DRUG INTERACTION | 19 | 0.39% |
| DRY MOUTH | 19 | 0.39% |
| BURNING SENSATION | 18 | 0.37% |
| MYOCARDIAL INFARCTION | 18 | 0.37% |
| SKIN DISCOLOURATION | 18 | 0.37% |
| SKIN EXFOLIATION | 18 | 0.37% |
| TREATMENT FAILURE | 18 | 0.37% |
| BLINDNESS | 17 | 0.35% |
| EYELID OEDEMA | 17 | 0.35% |
| EYELIDS PRURITUS | 17 | 0.35% |
| PNEUMONIA | 17 | 0.35% |
| SWELLING OF EYELID | 17 | 0.35% |
| ARRHYTHMIA | 16 | 0.33% |
| CHEST DISCOMFORT | 16 | 0.33% |
| PAIN IN EXTREMITY | 16 | 0.33% |
| PARAESTHESIA | 16 | 0.33% |
| SWELLING FACE | 16 | 0.33% |
| ABDOMINAL DISCOMFORT | 15 | 0.31% |
| BACK PAIN | 15 | 0.31% |
| DYSGEUSIA | 15 | 0.31% |
| EYELID MARGIN CRUSTING | 15 | 0.31% |
| HALLUCINATION | 15 | 0.31% |
| MUSCLE SPASMS | 15 | 0.31% |
| OVERDOSE | 15 | 0.31% |
| PALPITATIONS | 15 | 0.31% |
| PRODUCT USE ISSUE | 15 | 0.31% |
| SOMNOLENCE | 15 | 0.31% |
| BLOOD GLUCOSE INCREASED | 14 | 0.29% |
| DEPRESSION | 14 | 0.29% |
| DRY SKIN | 14 | 0.29% |
| EYE HAEMORRHAGE | 14 | 0.29% |
| INCORRECT DOSE ADMINISTERED | 14 | 0.29% |
| PEMPHIGOID | 14 | 0.29% |
| PERIPHERAL SWELLING | 14 | 0.29% |
| PRODUCT USE IN UNAPPROVED INDICATION | 14 | 0.29% |
| THROAT IRRITATION | 14 | 0.29% |
| URTICARIA | 14 | 0.29% |
| WEIGHT DECREASED | 14 | 0.29% |
| ABDOMINAL PAIN UPPER | 13 | 0.27% |
| Total | 4820 | |